$51.65−1.52 (−2.86%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Cytokinetics (CYTK) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
10 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue compounds ~5.7%/yr (FY21→FY25), net margin −891.6%. Worth your attention in FY25: Share count (+56.2%) and Capex step-up ($24.8M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲376.6%
88.0
FY21→FY25CAGR +5.7%/yr
Net income ($M)▼33.2%
−785.0
FY21→FY25CAGR —
Free cash flow ($M)▼33.8%
−534.8
capex stepped upCAGR —
Diluted EPS▼24.3%
−6.54
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+56.2%
76.9mn → 120.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$24.8M
▲535% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-892¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -891.6% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 113.3 | 88.0 | 18.5 | 7.5 | 94.6 | 70.4 | ▲376.6% | +5.7% |
Cost of revenue | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 109.6 | —A | —A | —A | —A | 70.4 | — | — |
Research & development | 402.9 | 416.0 | 339.4 | 330.1 | 240.8 | 159.9 | ▲22.6% | +27.0% |
Selling, general & admin | 414.2 | 284.3 | 215.3 | 173.6 | 178.0 | 96.8 | ▲32.0% | +30.9% |
Total operating expenses | 817.8 | 700.3 | 554.7 | 503.7 | 418.8 | 256.7 | ▲26.2% | +28.5% |
Operating incomefeeds ROC rank | −708.2 | −612.3 | −536.2 | −496.2 | −324.2 | −186.3 | ▼14.2% | — |
Other income, net | −122.0 | −221.1 | −104.8 | −57.7 | −76.1 | −29.3 | — | — |
Pretax income | −830.2 | −833.4 | −641.1 | −553.9 | −400.3 | −215.6 | ▼30.0% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −777.9 | −785.0 | −589.5 | −526.2 | −389.0 | −215.3 | ▼33.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −6.05 | −6.54 | −5.26 | −5.45 | −4.33 | −2.80 | ▼24.3% | — |
Diluted shares (mn) | 139.04 | 120.10 | 111.98 | 96.52 | 89.83 | 76.89 | ▲7.3% | +11.8% |
| Margins | ||||||||
Gross margin94th pct in Healthcare | 96.7% | —A | —A | —A | —A | 100.0% | — | — |
Operating margin | −625.2% | −695.4% | −2902.7% | −6589.7% | −342.8% | −264.5% | ▲2207.3pp | −430.9pp |
Net margin4th pct in Healthcare | −686.6% | −891.6% | −3191.1% | −6988.6% | −411.2% | −305.7% | ▲2299.5pp | −585.9pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Cytokinetics' revenue last fiscal year?
Cytokinetics reported revenue of $88.0M in fiscal 2025, up 376.6% from fiscal 2024.
What was Cytokinetics' net income?
Cytokinetics reported net income of −$785.0M in fiscal 2025, a net margin of −891.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

